<DOC>
	<DOCNO>NCT00424203</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give doxorubicin together cyclophosphamide work treat old woman stage I , stage II , stage III breast cancer remove surgery .</brief_summary>
	<brief_title>Doxorubicin Cyclophosphamide Treating Older Women With Stage I , Stage II , Stage III Breast Cancer That Has Been Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine independence old woman resect stage I , II , III breast cancer treat adjuvant doxorubicin hydrochloride cyclophosphamide . Secondary - Determine impact regimen aspects patient 's life , utilize Comprehensive Geriatric Assessment , Mini-Nutritional Assessment , Folstein Mini-Mental State Exam , Geriatric Depression Scale , Cumulative Illness Rating Scale-Geriatrics . - Determine quality life patient treat regimen . - Determine acceptability regimen patient . - Determine toxicity regimen , term cardiac issue anemia , patient . - Determine recurrence-free survival , event-free survival , overall survival patient treat regimen . OUTLINE : This pilot , nonrandomized , multicenter study . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Patients complete questionnaire baseline completion chemotherapy . Questionnaires include Comprehensive Geriatric Assessment , Mini-Nutritional Assessment ( malnutrition ) , Folstein Mini-Mental State Exam ( cognitive function ) , Geriatric Depression Scale ( depression ) , Cumulative Illness Rating Scale - Geriatrics ( comorbidities ) , EORTC Quality Life Questionnaire Core 30 ( quality life ) . After completion study therapy , patient follow every 3 month 4 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive adenocarcinoma breast Stage I , II III disease pN+ pN0 grade III disease ( tumor size ≥ 2 cm ) No metastatic disease Must undergone prior conservative radical surgery include axillary lymph node sentinel node dissection No residual tumor Negative margin Hormone receptor status : Estrogen receptor progesterone receptor negative PATIENT CHARACTERISTICS : Female Postmenopausal Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10 g/dL Alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.25 time ULN AST ALT &lt; 2.5 time ULN Creatinine clearance ≥ 40 mL/min No contraindication receive anthracyclines alkalize agent FEV normal Activities Daily Living ( ADL ) score ≥ 5 No decrease ≥ 1 point within past 3 month None follow baseline : Cognitive deficiency ( Folstein MiniMental State &lt; 25 ) Severe depression ( Geriatric Depression Scale ≥ 20 ) Severe malnutrition ( MiniNutritional Assessment ≤ 17 ) No serious comorbid condition ( Cumulative Illness Rating Scale Geriatrics grade 34 ) , include follow : Cardiac insufficiency Unstable angina Myocardiopathy Myocardial infarction within past year Uncontrolled hypertension Uncontrolled highrisk arrhythmia Severe medullary insufficiency Neurological psychological condition would preclude study consent Uncontrolled active infection Severe urinary tract infection Preexisting hematuria Active ulcer Uncontrolled diabetes No cancer within past 5 year except basal cell skin cancer carcinoma situ cervix No familial , geographical , social , psychological condition would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 60 day since prior therapeutic surgery At least 4 week since prior investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>depression</keyword>
	<keyword>malnutrition</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
</DOC>